30 C
Vientiane
Sunday, May 4, 2025
spot_img
Home Blog Page 1542

ROSEN, GLOBAL INVESTOR COUNSEL, Encourages Cutera, Inc. Investors with Losses to Secure Counsel Before Important Deadline in Securities Class Action – CUTR

New York, New York – Newsfile Corp. – July 6, 2023 – WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Cutera, Inc. (NASDAQ: CUTR) between February 17, 2021 and May 9, 2023, both dates inclusive (the “Class Period”) of the important July 24, 2023 lead plaintiff deadline.

SO WHAT: If you purchased Cutera securities during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement.

WHAT TO DO NEXT: To join the Cutera class action, go to https://rosenlegal.com/submit-form/?case_id=16520 or call Phillip Kim, Esq. toll-free at 866-767-3653 or email pkim@rosenlegal.com or cases@rosenlegal.com for information on the class action. A class action lawsuit has already been filed. If you wish to serve as lead plaintiff, you must move the Court no later than July 24, 2023. A lead plaintiff is a representative party acting on behalf of other class members in directing the litigation.

WHY ROSEN LAW: We encourage investors to select qualified counsel with a track record of success in leadership roles. Often, firms issuing notices do not have comparable experience, resources or any meaningful peer recognition. Many of these firms do not actually litigate securities class actions, but are merely middlemen that refer clients or partner with law firms that actually litigate the cases. Be wise in selecting counsel. The Rosen Law Firm represents investors throughout the globe, concentrating its practice in securities class actions and shareholder derivative litigation. Rosen Law Firm has achieved the largest ever securities class action settlement against a Chinese Company. Rosen Law Firm was Ranked No. 1 by ISS Securities Class Action Services for number of securities class action settlements in 2017. The firm has been ranked in the top 4 each year since 2013 and has recovered hundreds of millions of dollars for investors. In 2019 alone the firm secured over $438 million for investors. In 2020, founding partner Laurence Rosen was named by law360 as a Titan of Plaintiffs’ Bar. Many of the firm’s attorneys have been recognized by Lawdragon and Super Lawyers.

DETAILS OF THE CASE: According to the lawsuit, defendants throughout the Class Period made false and/or misleading statements and/or failed to disclose that: (1) overstated the sustainability of Cutera’s revenue growth; (2) failed to disclose significant conflicts among members of the Company’s senior leadership and Board; (3) failed to disclose several material weaknesses in the Company’s internal control over financial reporting; and (4) as a result of the foregoing, and the significant decline in the market value of the Company’s common stock, Plaintiff and other members of the Class suffered significant damages. When the true details entered the market, the lawsuit claims that investors suffered damages.

To join the Cutera class action, go to https://rosenlegal.com/submit-form/?case_id=16520 or call Phillip Kim, Esq. toll-free at 866-767-3653 or email pkim@rosenlegal.com or cases@rosenlegal.com for information on the class action.

No Class Has Been Certified. Until a class is certified, you are not represented by counsel unless you retain one. You may select counsel of your choice. You may also remain an absent class member and do nothing at this point. An investor’s ability to share in any potential future recovery is not dependent upon serving as lead plaintiff.

Follow us for updates on LinkedIn: https://www.linkedin.com/company/the-rosen-law-firm, on Twitter: https://twitter.com/rosen_firm or on Facebook: https://www.facebook.com/rosenlawfirm/.

Attorney Advertising. Prior results do not guarantee a similar outcome.

——————————-

Contact Information:

Laurence Rosen, Esq.
Phillip Kim, Esq.
The Rosen Law Firm, P.A.
275 Madison Avenue, 40th Floor
New York, NY 10016
Tel: (212) 686-1060
Toll Free: (866) 767-3653
Fax: (212) 202-3827
lrosen@rosenlegal.com
pkim@rosenlegal.com
cases@rosenlegal.com
www.rosenlegal.com

The issuer is solely responsible for the content of this announcement.

ROSEN, RECOGNIZED INVESTOR COUNSEL, Encourages Microvast Holdings, Inc. Investors With Losses to Inquire About Securities Class Action Investigation – MVST, MVSTW

New York, New York – Newsfile Corp. – July 6, 2023 – WHY: Rosen Law Firm, a global investor rights law firm, continues to investigate potential securities claims on behalf of shareholders of Microvast Holdings, Inc. (NASDAQ: MVST) (NASDAQ: MVSTW) resulting from allegations that Microvast may have issued materially misleading business information to the investing public.

SO WHAT: If you purchased Microvast securities you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement. The Rosen Law Firm is preparing a class action seeking recovery of investor losses.

WHAT TO DO NEXT: To join the prospective class action, go to https://rosenlegal.com/submit-form/?case_id=16538 or call Phillip Kim, Esq. toll-free at 866-767-3653 or email pkim@rosenlegal.com or cases@rosenlegal.com for information on the class action.

WHAT IS THIS ABOUT: On May 22, 2023, Reuters reported that the U.S. Department of Energy (DoE) canceled a $200M grant to lithium battery manufacturer, Microvast, citing lawmakers’ concerns over Microvast’s alleged links to the Chinese Communist Party. Microvast has been in talks with the DoE over the grant to help build a plant in Tennessee to support its work with General Motors developing specialized electric vehicle batteries.

On this news, Microvast’s stock price fell $0.80 per share, or 36.36% to close at $1.40 per share on May 23, 2023.

WHY ROSEN LAW: We encourage investors to select qualified counsel with a track record of success in leadership roles. Often, firms issuing notices do not have comparable experience, resources, or any meaningful peer recognition. Many of these firms do not actually litigate securities class actions. Be wise in selecting counsel. The Rosen Law Firm represents investors throughout the globe, concentrating its practice in securities class actions and shareholder derivative litigation. Rosen Law Firm has achieved the largest ever securities class action settlement against a Chinese Company. Rosen Law Firm was Ranked No. 1 by ISS Securities Class Action Services for number of securities class action settlements in 2017. The firm has been ranked in the top 4 each year since 2013 and has recovered hundreds of millions of dollars for investors. In 2019 alone the firm secured over $438 million for investors. In 2020, founding partner Laurence Rosen was named by law360 as a Titan of Plaintiffs’ Bar. Many of the firm’s attorneys have been recognized by Lawdragon and Super Lawyers.

Follow us for updates on LinkedIn: https://www.linkedin.com/company/the-rosen-law-firm, on Twitter: https://twitter.com/rosen_firm or on Facebook: https://www.facebook.com/rosenlawfirm/.

Attorney Advertising. Prior results do not guarantee a similar outcome.

——————————-

Contact Information:

Laurence Rosen, Esq.
Phillip Kim, Esq.
The Rosen Law Firm, P.A.
275 Madison Avenue, 40th Floor
New York, NY 10016
Tel: (212) 686-1060
Toll Free: (866) 767-3653
Fax: (212) 202-3827
lrosen@rosenlegal.com
pkim@rosenlegal.com
cases@rosenlegal.com
www.rosenlegal.com

The issuer is solely responsible for the content of this announcement.

ROSEN, GLOBAL INVESTOR COUNSEL, Encourages JinkoSolar Holding Co., Ltd. Investors to Inquire About Securities Class Action Investigation – JKS

New York, New York – Newsfile Corp. – July 6, 2023 – WHY: Rosen Law Firm, a global investor rights law firm, continues to investigate potential securities claims on behalf of shareholders of JinkoSolar Holding Co., Ltd (NYSE: JKS) resulting from allegations that JinkoSolar may have issued materially misleading business information to the investing public.

SO WHAT: If you purchased JinkoSolar securities you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement. The Rosen Law Firm is preparing a class action seeking recovery of investor losses.

WHAT TO DO NEXT: To join the prospective class action, go to https://rosenlegal.com/submit-form/?case_id=16025 or call Phillip Kim, Esq. toll-free at 866-767-3653 or email pkim@rosenlegal.com or cases@rosenlegal.com for information on the class action.

WHAT IS THIS ABOUT: On May 9, 2023, before trading hours, the Jacksonville Daily Record published an article entitled “Federal agents issue search warrant at JinkoSolar plant in Cecil Commerce Center: Homeland Security said it is part of an ongoing investigation; the factory, whose parent company is in China, opened in Jacksonville in 2018.” The Jacksonville Daily Record reported that “[a]ccording to the Federal Bureau of Investigation, federal agents were assisting the Department of Homeland Security with the execution of a search warrant.” Further, the article cited WJXT News4Jax, stating that JinkoSolar is one of several companies under investigation by the U.S. Commerce Department for circumventing trade rules by sending products to other countries before moving them to the U.S.

On this news, JinkoSolar’s American depositary receipt (“ADR”) price fell $3.91 per ADR, or 8%, to close at $43.47 per ADR on May 9, 2023, on unusually heavy trading volume.

WHY ROSEN LAW: We encourage investors to select qualified counsel with a track record of success in leadership roles. Often, firms issuing notices do not have comparable experience, resources, or any meaningful peer recognition. Many of these firms do not actually litigate securities class actions. Be wise in selecting counsel. The Rosen Law Firm represents investors throughout the globe, concentrating its practice in securities class actions and shareholder derivative litigation. Rosen Law Firm has achieved the largest ever securities class action settlement against a Chinese Company. Rosen Law Firm was Ranked No. 1 by ISS Securities Class Action Services for number of securities class action settlements in 2017. The firm has been ranked in the top 4 each year since 2013 and has recovered hundreds of millions of dollars for investors. In 2019 alone the firm secured over $438 million for investors. In 2020, founding partner Laurence Rosen was named by law360 as a Titan of Plaintiffs’ Bar. Many of the firm’s attorneys have been recognized by Lawdragon and Super Lawyers.

Follow us for updates on LinkedIn: https://www.linkedin.com/company/the-rosen-law-firm, on Twitter: https://twitter.com/rosen_firm or on Facebook: https://www.facebook.com/rosenlawfirm/.

Attorney Advertising. Prior results do not guarantee a similar outcome.

——————————-

Contact Information:

Laurence Rosen, Esq.
Phillip Kim, Esq.
The Rosen Law Firm, P.A.
275 Madison Avenue, 40th Floor
New York, NY 10016
Tel: (212) 686-1060
Toll Free: (866) 767-3653
Fax: (212) 202-3827
lrosen@rosenlegal.com
pkim@rosenlegal.com
cases@rosenlegal.com
www.rosenlegal.com

The issuer is solely responsible for the content of this announcement.

ROSEN, TRUSTED INVESTOR COUNSEL, Encourages Fox Corporation Investors to Inquire About Securities Class Action Investigation – FOX, FOXA

New York, New York – Newsfile Corp. – July 6, 2023 – WHY: Rosen Law Firm, a global investor rights law firm, continues to investigate potential securities claims on behalf of shareholders of Fox Corporation (NASDAQ: FOX) (NASDAQ: FOXA) resulting from allegations that FOX may have issued materially misleading business information to the investing public. The prospective class includes those who purchased FOX call options and/or sold put options.

SO WHAT: If you purchased FOX securities you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement. The Rosen Law Firm is preparing a class action seeking recovery of investor losses.

WHAT TO DO NEXT: To join the prospective class action, go to https://rosenlegal.com/submit-form/?case_id=13327 or call Phillip Kim, Esq. toll-free at 866-767-3653 or email pkim@rosenlegal.com or cases@rosenlegal.com for information on the class action.

WHAT IS THIS ABOUT: In the wake of the 2020 U.S. Presidential Election, Dominion Voting Systems sued FOX for defamation. Dominion’s lawsuit alleges that FOX defamed Dominion’s business by endorsing, repeating or broadcasting a series of “verifiably false yet devastating lies about Dominion.” Dominion claims that various statements that were made on FOX News, including that Dominion committed election fraud by rigging the 2020 election, that Dominion’s software and algorithms manipulated vote counts in the 2020 election, that Dominion was founded for the purpose of rigging elections, and that Dominion paid kickbacks to government officials who used its machines, were defamatory and false. Dominion and Fox eventually agreed to settle the case for $787 million.

Beginning in February 2023, specific details emerged of internal discussions at FOX in the wake of the 2020 election, revealing that FOX’s senior leaders understood that claims to the effect that Dominion and other entities had rigged the 2020 election were false. As a consequence, FOX faces significant potential legal liability.

As a result of ongoing revelations about FOX’s legal exposure in the Dominion lawsuit, FOX’s Class A stock has declined from a closing price of $37.03 on February 17, 2023 to a closing price of $32.52 on March 15, 2023, a 12% decline. FOX’s Class B stock has declined from a closing price of $34.22 on February 17, 2023 to a closing price of $29.83 on March 15, 2023, a 12% decline.

WHY ROSEN LAW: We encourage investors to select qualified counsel with a track record of success in leadership roles. Often, firms issuing notices do not have comparable experience, resources or any meaningful peer recognition. Be wise in selecting counsel. The Rosen Law Firm represents investors throughout the globe, concentrating its practice in securities class actions and shareholder derivative litigation. Rosen Law Firm has achieved the largest ever securities class action settlement against a Chinese Company. Rosen Law Firm was Ranked No. 1 by ISS Securities Class Action Services for number of securities class action settlements in 2017. The firm has been ranked in the top 4 each year since 2013 and has recovered hundreds of millions of dollars for investors. In 2019 alone the firm secured over $438 million for investors. In 2020, founding partner Laurence Rosen was named by law360 as a Titan of Plaintiffs’ Bar. Many of the firm’s attorneys have been recognized by Lawdragon and Super Lawyers.

Follow us for updates on LinkedIn: https://www.linkedin.com/company/the-rosen-law-firm, on Twitter: https://twitter.com/rosen_firm or on Facebook: https://www.facebook.com/rosenlawfirm/.

Attorney Advertising. Prior results do not guarantee a similar outcome.

——————————-

Contact Information:

Laurence Rosen, Esq.
Phillip Kim, Esq.
The Rosen Law Firm, P.A.
275 Madison Avenue, 40th Floor
New York, NY 10016
Tel: (212) 686-1060
Toll Free: (866) 767-3653
Fax: (212) 202-3827
lrosen@rosenlegal.com
pkim@rosenlegal.com
cases@rosenlegal.com
www.rosenlegal.com

The issuer is solely responsible for the content of this announcement.

Secarna Pharmaceuticals publishes new preclinical data in The Journal of Immunology demonstrating potent therapeutic activity of LNAplus™ ASO targeting NLRP3 in highly debilitating autoinflammatory diseases

  • Secarna’s LNAplus™ ASOs suppress expression of NLRP3, a central component of the inflammasome pathway, which is overactive in many inflammatory diseases
  • Cryopyrin-associated periodic syndrome (CAPS) is a group of rare inherited autoinflammatory diseases driven by overactive NLRP3, resulting in systemic inflammation
  • With NLRP3-specific ASOs, inflammatory downstream effects were interrupted in immune cells and strong symptom relief and significant prolongation of survival was achieved in a CAPS disease model.

MUNICH/MARTINSRIED, GERMANY – EQS Newswire – 6 July 2023 – Secarna Pharmaceuticals GmbH & Co. KG (“Secarna”), a biopharmaceutical company focusing on the discovery and development of next-generation antisense oligonucleotide (ASO) therapies to address challenging or previously undruggable targets via its LNAplus™ platform, announced today the publication of compelling new preclinical data supporting the use of ASOs for the treatment of inflammatory diseases in the peer-reviewed journal, The Journal of Immunology. The article, “Antisense oligonucleotide therapy decreases IL-1β expression and prolongs survival in mutant Nlrp3 mice”, addresses the joint work of the groups of Prof. Ariel Feldstein and Prof. Hal Hoffman from the University of California San Diego, world-leading specialists in the field of NLRP3-mediated inflammation and CAPS, and Secarna and can be found here.

Using its proprietary Oligofyer™ bioinformatics system, Secarna designed LNAplus™ ASOs to specifically suppress the expression of the NLR family pyrin domain containing 3 (NLRP3), the central component of the inflammasome pathway. Activation of the inflammasome results in release of proinflammatory cytokines such as IL-1β. Overactivation of this pathway has a pathological role in many diseases with an inflammatory component, such as arthritis, inflammatory bowel disease, acute and chronic kidney disease, non-alcoholic steatohepatitis, asthma and also diseases of the central nervous system, such as Parkinson’s disease and Alzheimer’s disease. The results of this study demonstrate that NLRP3-specific ASO treatment downregulates NLRP3 expression and IL-1β release in the CAPS disease model, suggesting ASO therapy as a potential treatment of CAPS or other NLRP3-mediated diseases.

CAPS are a spectrum of autoinflammatory diseases caused by activating mutations in the NLRP3 gene. Depending on the type of mutation, symptoms and disease severity, they are divided into neonatal onset multisystem inflammatory disease (NOMID), Muckle Wells syndrome (MWS), and familial cold autoinflammatory syndrome (FCAS). Symptoms are heterogeneous and can include fever, urticarial rash but also multiple neurological manifestations that can be debilitating and have a severe impact on quality of life. Current therapies have been designed to inhibit the IL-1β pathway and have been shown to improve clinical symptoms in patients. However, there remains an unmet clinical need for patients who do not respond adequately, emphasizing the need for improved therapies.

“With the publication of these preclinical results, we have demonstrated that NLRP3-specific ASOs can effectively target this gene across the CAPS spectrum and therefore block the overactivation of the inflammatory cascade,” said Frank Jaschinski, Ph.D., Chief Scientific Officer of Secarna Pharmaceuticals. “We are excited to see that in a particularly aggressive model of CAPS clear therapeutic benefits on different readouts in relevant organs were achieved by NLRP3-ASO treatment. Furthermore, the data open the door for these ASOs to treat other diseases driven by an overactive NLRP3 inflammasome pathway, such as inflammatory bowel disease, acute and chronic kidney disease, and diseases of the central nervous system. I very much look forward to seeing the development of ASOs targeting inflammation, a field where, to date, there is no approved ASO treatment.”

The groups from the University of California San Diego tested the potential of the NLRP3-ASOs for treatment of CAPS in in vitro and in vivo models. In cell culture they demonstrated that NLRP3-ASOs potently suppressed expression of the gene. Furthermore, there was a strong reduction in the secretion of the proinflammatory cytokine IL-1β in immune cell cultures derived from in vivo models from all three types of CAPS. The activity of NLRP3-ASO was tested in an in vivo NOMID disease model; NOMID is the most severe form of CAPS. After systemic ASO treatment, life expectancy was significantly increased, with weight gains and reductions in the severity of skin lesions, showing an overall reduction in systemic inflammation.

Hashtag: #SecarnaPharmaceuticals

The issuer is solely responsible for the content of this announcement.

About Secarna’s proprietary drug discovery and development platform, LNAplus™

Secarna’s proprietary, customized LNAplus™ platform is being applied to the discovery, testing and selection of antisense oligonucleotides (ASOs) for pre-clinical and clinical development. LNAplus™ encompasses all aspects of drug discovery and pre-clinical development and has proven to be fast, reliable, scalable and efficient, enabling the discovery of novel antisense-based therapies for challenging or currently undruggable targets. The platform includes the powerful proprietary Oligofyer™ bioinformatics pipeline, a streamlined, high efficiency screening process, including Secarna’s proprietary LNA-Vit(r)ox™ safety test system, as well as target-specific functional assays. Secarna’s platform and ASOs have been validated by numerous in-house projects as well as in several academic and industry collaborations.

About Secarna Pharmaceuticals GmbH & Co. KG
Secarna Pharmaceuticals is the leading independent European next-generation antisense drug discovery and development company addressing high unmet medical needs in immuno-oncology and immunology, as well as viral, neurodegenerative and cardiometabolic diseases. Secarna’s mission is to maximize the performance and output of its proprietary LNAplus™ antisense oligonucleotide discovery platform, as well as to develop highly specific, safe, and efficacious best-in-class antisense therapies. With over 20 discovery and development programs, including both proprietary pipeline projects and partnered programs, Secarna focuses on targets in indications where antisense-based approaches have clear potential benefits over other therapeutic modalities.

Cushman & Wakefield: Hong Kong Retail Market in Gradual 1H Recovery Since Border Reopening, Office Leasing Market Yet to Stage Significant Rebound

Residential Transaction Slowdown Since May as More Buyers Turn Cautious in Rate Hike Environment

  • Retail sentiment continues to rebound, with high street rents maintaining low-single-digit growth, vacancy rates further dropping across districts, and pharmacy sector the most active for expansion
  • Overall Grade A office net absorption in Q2 recorded -172,700 sq ft as leasing activity is yet to rebound significantly, some tenants taking advantage of lower rents for flight-to-quality moves
  • Initial boost from border reopening on residential market fades, as high interest rate environment suppresses housing transactions and price performance

HONG KONG SAR – Media OutReach – 6 July 2023 – Global real estate services firm Cushman & Wakefield today published its Hong Kong Property Markets Review and Outlook 1H 2023 report. Hong Kong’s regular economic activity levels have gradually resumed as the city fully reopened its border, supporting a recovery of tourist spending in the retail market. Total retail sales reached $171.9 billion in the first five months of the year, up 21.0% y-o-y. However, the office leasing market has yet to see a notable rebound, with negative absorption continuing into Q2. The overall office availability rate rose slightly to 17.3%, further weighing on rental levels. In the residential market, buyers have become more hesitant to enter transactions given the higher interest rates, leading to a 13% q-o-q decline in the number of transactions in Q2. Home prices also started to fluctuate towards the end of the quarter.

Office Market — Net Absorption Still Negative in Q2 as Corporates Remain Cautious

Overall business sentiment strengthened after Hong Kong fully reopened its border, although the return of cross-border activity to normalcy did not alleviate companies’ caution amid an uncertain global economic outlook. The office leasing market has not yet seen a significant rebound, while leasing activity by mainland enterprises in Hong Kong has yet to meet expectations. Hong Kong’s Grade A office market recorded net absorption of -172,700 sq ft in Q2, mainly due to downsizing by multinational companies during the quarter, notably in Greater Tsimshatsui and Greater Central. However, this is an improvement from the -248,200 sq ft recorded in Q1. The overall availability rate has slightly increased from 17.1% in Q1 to 17.3% in Q2, in turn exerting further downwards pressure on Grade A office rents, which fell by 2.1% q-o-q and 3.6% YTD, with the most notable drop observed in Hong Kong East.

John Siu, Managing Director, Head of Project and Occupier Services, Hong Kong, Cushman & Wakefieldstated: “In terms of new leasing transactions, the share of new transactions by area across business sectors was distributed more evenly in Q2. While the banking and finance sector still accounts for the largest share of newly leased space (25%), the medical/health/beauty, consumer products/manufacturing, and insurance sectors have each contributed more than 10%. The increase in demand for medical/health/beauty and insurance services from mainland visitors since the border reopening has driven up office space requirements from these sectors. Looking ahead to 2H, several large new office buildings are expected to be completed, and this, added to the existing high office availability, has hindered the rebound in office rents. Overall office rents are expected to further adjust in 2H, with a forecast of a 5-7% decline for 2023. With the recent signs of improving Sino-U.S. relations, it is expected that the gradual return of the economy and cross-border activities will support business confidence and expansion plans, which could aid the office market to recover.”

Retail Market — High Street Rents Improve as Vacancy Rates Further Decline, yet Larger Retail Brands Remain Wait-and-See

Hong Kong’s retail market has been gradually recovering thanks to the resumption of tourist spending. Total retail sales from January to May totaled HK$171.9 billion, recording a significant y-o-y increase of 21.0% due to the lower base last year. Among retail sectors, Jewellery & Watches, Fashion & Accessories and Medicines & Cosmetics, popular product categories among tourists, continued to outperform, with y-o-y growth rates of 76.6%, 54.0% and 37.4%, respectively. The overall high street vacancy rate continued to trend downwards across submarkets, with an average vacancy rate of approximately 9%, the lowest in the past three years. As for high street retail rents, all districts recorded low single-digit q-o-q growth in Q2, bringing an average rise of approximately 5% for 1H 2023. Central district saw the strongest increase of 7.1%, supported by both high-end tourists and local consumption. In addition, F&B rents continued to rise steadily, with 1H 2023 growth of 5% to 6% across different districts.

Kevin Lam, Executive Director, Head of Retail Services, Agency & Management, Hong Kong, Cushman & Wakefield stated, “Since the border reopened, drug stores and pharmacies have been the predominant driving force of new leasing activities in the core districts. The spending pattern of mainlanders has changed from “shopping-centric” to more “experience-based” tourism, which has paused the expansion plans of some high-end retailers and large brand chains. Although there have been some recent leasing transactions for luxury brands, most of them are for relocation and consolidation purposes, hence making it difficult to foresee a significant rebound of rental growth in the short term. As well, we have seen that following the border reopening, the travel outflow of locals is greater than the inflow of tourists to Hong Kong, which could diminish some local consumption power. As a result, the retail market during the Labor Day and the Buddha’s Birthday holiday periods was not as active as hoped-for. Therefore, we are conservative on the rental projection for 2H this year, depending on tourist arrival numbers in the first summer vacation period since the onset of the pandemic.”

Residential Market — High Interest Rates Slow Buying Sentiment, Housing Prices Expected to Rise From 3% to 7% for 2023

The housing market witnessed an initial recovery in prices and transaction volume following the border reopening in February. However, the subsequent interest rate hikes in May, coupled with global stock market volatility, have dampened potential buyers’ appetites towards the later-half of Q2.

Around 12,200 residential transactions were recorded in Q2, down 13% q-o-q and down 18% y-o-y. Developers have continued to actively launch new projects at the market rate, further thinning purchasing power in the secondary market. Primary market housing transactions accounted for around 24% of total residential transactions between January and May.

According to the latest government data, overall residential prices turned negative in May after rising for the previous four months, dropping 0.7% m-o-m. However, the first five months still recorded a cumulative increase of 4.9%. According to Cushman & Wakefield’s latest data on popular housing estates price levels, some have declined in the past two months and hence have offset some of the Q1 gains. The price level in City One Shatin, representing the mass market, was down by 3.0% q-o-q in Q2 (1H 2023 up 16.4%); Taikoo Shing, in the middle market, was down 3.9% q-o-q (1H 2023 up 6.9%); while Residence Bel-Air, representing the luxury market bracket, dropped 1.1% q-o-q (1H 2023 up 4.2%).

Rosanna Tang, Executive Director, Head of Research, Hong Kong, Cushman & Wakefield, said: “Although the market believes that interest rates may peak in 2H, the consensus is that the high interest rate environment will persist for quite some time. In addition, the recent stock market volatility, geopolitical instability, and slow recovery of the global economy, has contributed to a more cautious buying sentiment and hence dampened the recovery process of residential transactions and prices. We expect developers to continue to actively launch their new projects in the 2H period, mostly of units at less than HK$10 million, with attractive pricing and packages, while transactions in the secondary market may remain relatively slow. In 2023, overall residential property prices are expected to rise by 3% to 7% for the year, while total residential transactions are expected to rise by 10% to 15% y-o-y to around 50,000 units.”

Please click here to download photos.

Photo caption:
John Siu, Managing Director, Head of Project and Occupier Services, Hong Kong, Cushman & Wakefield (middle); Kevin Lam, Executive Director, Head of Retail Services, Agency & Management, Hong Kong, Cushman & Wakefield (left) and Rosanna Tang, Executive Director, Head of Research, Hong Kong, Cushman & Wakefield (right)

Hashtag: #Cushman&Wakefield

The issuer is solely responsible for the content of this announcement.

About Cushman & Wakefield

Cushman & Wakefield (NYSE: CWK) is a leading global commercial real estate services firm for property owners and occupiers with approximately 52,000 employees in approximately 400 offices and 60 countries. In Greater China, a network of 23 offices serves local markets across the region. In 2022, the firm reported global revenue of US$10.1 billion across its core services of valuation, consulting, project & development services, capital markets, project & occupier services, industrial & logistics, retail and others. It also receives numerous industry and business accolades for its award-winning culture and commitment to Diversity, Equity and Inclusion (DEI), Environmental, Social and Governance (ESG) and more. For additional information, visit www.cushmanwakefield.com.hk or follow us on LinkedIn ().

Spackman Entertainment Group Set To Release Upcoming Action Film, A MAN OF REASON, On August 15 In Korea

  • A MAN OF REASON, an action feature film produced by the Group’s wholly‐owned indirect subsidiary, Studio Take, marks the directorial debut of Korean star Jung Woo-sung, internationally known for his role in STEEL RAIN (2017) and the Group’s hit production, COLD EYES (2013)
  • Garnering widespread international recognition, A MAN OF REASON premiered at the 42nd Hawaii International Film Festival in the US, and was invited to the 47th Toronto International Film Festival in Canada and the 55th Sitges Film Festival in Spain
  • A MAN OF REASON also headlines Park Sung-woong and Kim Nam-gil, who starred in Spackman Entertainment Group’s previous films, FOR THE EMPEROR (2014) and LOVERS VANISHED (2010), respectively

SINGAPORE – Media OutReach – 6 July 2023 Spackman Entertainment Group Limited (the “Group“), one of Korea’s leading entertainment production groups founded in 2011 by global media & technology investor Charles Spackman, wishes to announce that the Group’s upcoming action feature film, A MAN OF REASON, produced by the Group’s wholly‐owned indirect subsidiary, Studio Take Co., Ltd. (“Studio Take“), is set to be released theatrically in Korea on August 15, 2023.

Studio Take’s A MAN OF REASON has already attracted global attention, premiering at the 42nd Hawaii International Film Festival in the US, with invitations to the 47th Toronto International Film Festival (“TIFF“) in Canada and the 55th Sitges Film Festival in Spain. A MAN OF REASON was notably selected as the Special Presentation of the 2022 Official Selection at TIFF, one of the world’s four major international film festivals. The production was praised for its impressive cinematography and compelling performances of its actors.

The film features the story of Soo-hyeok (played by Jung Woo-sung), a man struggling to live a normal life after spending ten years in prison on behalf of his gang boss. The narrative unfolds as Soo-hyeok discovers he is a father and attempts to sever ties with his former gang, only to have the boss hire a notorious killer to take his daughter hostage. He decides to seek revenge, setting the stage for an intense, action-filled drama.

Co-starring in the movie are Park Sung-woong of FOR THE EMPEROR (2014) and Kim Nam-gil of LOVERS VANISHED (2010), both films previously produced by the Group. The movie is distributed by Acemaker Movie Works. North American distribution rights have been acquired by the independent film and television studio, Epic Pictures Group, known for distributing genre films in the US and Canada.

A MAN OF REASON further adds to Studio Take’s record of exceptional filmmaking, following in the footsteps of their previous works, including the musical film THE BOX (2021), featuring EXO’s Chanyeol, and the art film STONE SKIPPING (2020), which earned an invitation to the 23rd Busan International Film Festival.

Moreover, Studio Take’s next promising project, THE GUEST, is currently in post-production and scheduled for release later this year. With a history of standout releases and compelling forthcoming projects, the Group is confident in Studio Take’s ongoing commitment to delivering a steady stream of top-tier cinema.

Hashtag: #SpackmanEntertainmentGroup

The issuer is solely responsible for the content of this announcement.

About Spackman Entertainment Group

Spackman Entertainment Group Limited (“SEGL” or the “Company“), and together with its subsidiaries, (the “Group“), is one of Korea’s leading entertainment production groups. SEGL is primarily engaged in the independent development, production, presentation, and financing of theatrical motion pictures in Korea.

The Company was founded in 2011 by renowned media and technology investor Charles Spackman who served as the Company’s Executive Chairman until 2017. For the past two decades, Mr. Charles Spackman has been a powerhouse in the Korean entertainment industry starting in the early 2000’s with the pioneering success of Sidus Pictures, the largest movie production company at the time and the first to be listed in Korea. Mr. Spackman is also the Founder, Chairman and Chief Executive Officer of the global investment firm, Spackman Group. For more information, please visit charlesspackman.com and spackman-group.com/charles-spackman.

Since its founding, SEGL had produced more than 30 major motion pictures including a number of the highest grossing and award-winning films in Korea, namely #ALIVE (2020), CRAZY ROMANCE (2019), DEFAULT (2018), MASTER (2016), THE PRIESTS (2015), SNOWPIERCER (2013), COLD EYES (2013) and ALL ABOUT MY WIFE (2012).

Our films are theatrically distributed and released in Korea and overseas markets, as well as for subsequent post-theatrical worldwide release in other forms of media, including online streaming, cable TV, broadcast TV, IPTV, video-on-demand, and home video/DVD, etc. Generally, we release our motion pictures into wide-theatrical exhibition initially in Korea, and then in overseas and ancillary markets.

The Group also invests into and produces Korean television dramas. In addition to our content business, we also own equity stakes in entertainment-related companies and film funds that can financially and strategically complement our existing core operations. SEGL is listed on the Catalist of the Singapore Exchange Securities Trading Limited under the ticker 40E.

Production Labels

SEGL owns a 100% equity interest in Studio Take Co., Ltd. (“Studio Take“) which produced STONE SKIPPING (2020) and THE BOX (2021). Its latest film, A MAN OF REASON, premiered in the US at the 42nd Hawaii International Film Festival. The film was also invited to the 47th Toronto International Film Festival, the largest film festival in North America, and the 55th Sitges Film Festival, one of the world’s top three genre film festivals. A MAN OF REASON is expected to be released in the third quarter of 2023. Studio Take shall also release an upcoming film, THE GUEST, which is at the post-production stage and scheduled to be released in the second half of this year.

SEGL owns Novus Mediacorp Co., Ltd. (“Novus Mediacorp“), an investor, presenter, and/or post-theatrical distributor for a total of 80 films (59 Korean and 21 foreign) including OKAY MADAM (2020), LONG LIVE THE KING (2019), MY FIRST CLIENT (2019), ROSE OF BETRAYAL (2018), THE OUTLAWS (2017) and SECRETLY, GREATLY (2013), which was one of the biggest box office hits of 2013 starring Kim Soo-hyun of MY LOVE FROM THE STARS (2013), as well as FRIEND 2: THE GREAT LEGACY (2013). In 2012, Novus Mediacorp was also the post-theatrical rights distributor of ALL ABOUT MY WIFE (2012), a top-grossing romantic comedy produced by Zip Cinema. In 2018, THE OUTLAWS, co-presented by Novus Mediacorp broke the all-time highest Video On Demand (“VOD“) sales records in Korea. For more information, please visit novusmediacorp.com.

The Company owns a 100% equity interest in Greenlight Content Limited (“Greenlight Content“) which is mainly involved in the business of investing into dramas and movies, as well as providing consulting services for the production of Korean content. Through the acquisition of Greenlight Content, the Group’s first co-produced drama, MY SECRET TERRIUS, starring top Korean star, So Ji Sub, achieved #1 in drama viewership ratings for its time slot and recorded double digits for its highest viewership ratings. Greenlight Content was one of the main investors of MY SECRET TERRIUS.

The Company owns a 100% equity interest in Simplex Films Limited (“Simplex Films“) which is an early stage film production firm. The maiden film of Simplex Films, JESTERS: THE GAME CHANGERS (2019), was released in Korea on 21 August 2019. Simplex Films has several line-up of films including HURRICANE BROTHERS (working title).

The Company owns a 20% equity interest in The Makers Studio Co. Ltd., which plans to produce and release four upcoming films, the first of which will be THE ISLAND OF THE GHOST’S WAIL, a comedy horror film.

Talent Representation

The Company holds an effective shareholding interest of 43.88% in Spackman Media Group Limited (“SMGL“). SMGL, a company incorporated in Hong Kong, together with its subsidiaries, is collectively one of the largest entertainment talent agencies in Korea in terms of the number of artists under management, including some of the top names in the Korean entertainment industry. SMGL operates its talent management business through renowned agencies such as SBD Entertainment Inc. (Son Suk-ku, Han Ji-hyun, Park Keun-rok), MSteam Entertainment Co., Ltd. (Son Ye-jin, Wi Ha-jun, Lee Min-jung, Ko Sung-hee, Lee Cho-hee), UAA&CO Inc. (Kim Sang-kyung) and Play Content Co., Ltd. (Hwang-hwi). Through these full-service talent agencies in Korea, SMGL represents and guides the professional careers of a leading roster of award-winning actors/actresses in the practice areas of motion pictures, television, commercial endorsements, and branded entertainment. SMGL leverages its unparalleled portfolio of artists as a platform to develop, produce, finance and own the highest quality of entertainment content projects, including theatrical motion pictures, variety shows and TV dramas. This platform also creates and derives opportunities for SMGL to make strategic investments in development stage businesses that can collaborate with SMGL artists. SMGL is an associated company of the Company. For more information, please visit spackmanmediagroup.com.

The Company owns a 100% equity interest in Constellation Agency Pte. Ltd. (“Constellation Agency“). Constellation Agency, which owns The P Factory Co., Ltd. (“The P Factory“) and Platform Media Group Co., Ltd. (“PMG“), is primarily involved in the business of overseas agency for Korean artists venturing into the overseas market. The P Factory is an innovative marketing solutions provider specializing in event and branded content production. PMG is a talent management agency, which represents and manages the careers of major artists in film, television, commercial endorsements and branded entertainment.

Strategic Businesses

The Company also operates a café-restaurant, Upper West, in the Gangnam district of Seoul and own a professional photography studio, noon pictures Co., Ltd.

For more details, please visit spackmanentertainmentgroup.com/

Alibaba Pictures’ “Lost in the Stars” Emerges as Summer Box Office Sensation in Resurgent Chinese Film Market

HONG KONG SAR – Media OutReach – 6 July 2023 – Mainland China’s film market has long been one of the most dynamic and promising in the world, and in the first half of this year, the Chinese film market experienced an exciting recovery. In particular, the recent release of “Lost in the Stars” (消失的她), in which Alibaba Pictures Group Limited (Stock code:1060, referred to as the “Company”) was heavily involved in the investment and distribution, has generated significant buzz at the box office and created a wave of movie-going frenzy. In just over 10 days since its release, the film’s box office receipts have exceeded RMB2.7 billion, equivalent to 9% of China’s total box office revenue last year, making it a dark horse at the box office and the opening of the summer season for the Company.

“Lost in the Stars” leads the way in the summer box office

As the primary producer, distributor, and promoter of the film, Alibaba Pictures has achieved a full-scale deployment in the production and marketing chain of “Lost in the Stars”, including investment, distribution, ticket sales and other aspects. “Lost in the Stars” is also the prelude to the Company’s rich lineup of 16 films for the summer season. The strong start to the season once again demonstrates the Company’s forward-looking planning in the content industry and the continuous improvement of its production and development capabilities.

After the Dragon Boat Festival, the summer box office season kicked off, and the number of scheduled films has exceeded 90 and continues to grow, making this year’s film market performance highly anticipated. According to data from Beacon Professional, as of 4pm, July 6, the total box office revenue (including pre-sales) of this year’s summer box office had exceeded RMB5.626 billion. The film “Lost in the Stars”, released by Alibaba Pictures and Taopiaopiao, continued its momentum as a dark horse at the box office during the Dragon Boat Festival, leading the summer box office. As of 4pm, July 6, the box office receipts of “Lost in the Stars” had exceeded RMB2.728 billion, making it one of the hottest films of the summer, and it is expected to become the top grossing film in the summer box office and post the largest attendance record in the past three years.

Alibaba Pictures continues to expand its presence in the entertainment industry

Alibaba Pictures has strong capabilities in film production, distribution, and promotion, and will further strengthen its presence in the pan-entertainment industry by enhancing its dual-engine strategy of “content and technology”, while building out its own unique entertainment ecosystem. The Company is making significant investments in a full range of entertainment content and enhancing its capabilities to produce a broader range of content, including film and drama series content, with a view to steadily delivering high-quality content to the market. It is also expanding the scope of its technology platform services and exploring business opportunities associated with digital humans and multiple business models for IP merchandising and commercialization, in order to provide consumers with a richer, better and more tangible product experience. Moreover, the Company is actively promoting its collaboration and cooperation within the Alibaba ecosystem, such as online live streaming, online ticketing, and film merchandising, to unlock the potential of “content + technology”.

In addition to investment and product layout, the Company also emphasizes cooperation and communication within the industry. Through cooperation with domestic and overseas film companies, directors, actors, and others, it brings more international elements to the development of China’s film industry and enhances the international visibility and influence of Chinese films.

In the future, with the recovery of China’s film market, Alibaba Pictures will continue to adhere to its dual-engine strategy and innovative spirit, strengthen cooperation with all parties, and continuously promote the development of China’s film industry to bring greater returns to investors.

Hashtag: #AlibabaPictures

The issuer is solely responsible for the content of this announcement.

About Alibaba Pictures

Alibaba Pictures is listed on the main board of The Stock Exchange of Hong Kong Limited (stock code: 1060). It is an Internet-driven integrated platform that covers content production, promotion and distribution, IP licensing, cinema ticketing management, and data services for the entertainment industry.

Alibaba Pictures’ company website: